ST2 overexpression is regularized after imatinib mesylate treatment, while IL-33 neutralizes in vitro imatinib mesylate-induced proliferation arrest in CML CD34 progenitors through activation of the STAT5 pathway. The gene discussed is IL33; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.